CL2020000056A1 - Nuevos derivados de xantina sustituidos. - Google Patents
Nuevos derivados de xantina sustituidos.Info
- Publication number
- CL2020000056A1 CL2020000056A1 CL2020000056A CL2020000056A CL2020000056A1 CL 2020000056 A1 CL2020000056 A1 CL 2020000056A1 CL 2020000056 A CL2020000056 A CL 2020000056A CL 2020000056 A CL2020000056 A CL 2020000056A CL 2020000056 A1 CL2020000056 A1 CL 2020000056A1
- Authority
- CL
- Chile
- Prior art keywords
- xanthine derivatives
- substituted xanthine
- new substituted
- derivatives
- trpc5
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE XANTINA SUSTITUIDOS, A COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y A SU USO EN TERAPIA, PARTICULARMENTE EN EL TRATAMIENTO DE ESTADOS QUE TIENEN UNA ASOCIACIÓN CON CANALES IÓNICOS QUE CONTIENEN TRPC5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17180721 | 2017-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000056A1 true CL2020000056A1 (es) | 2020-06-12 |
Family
ID=59325162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000056A CL2020000056A1 (es) | 2017-07-11 | 2020-01-08 | Nuevos derivados de xantina sustituidos. |
Country Status (30)
Country | Link |
---|---|
US (1) | US10329292B2 (es) |
EP (1) | EP3652176B1 (es) |
JP (1) | JP7114702B2 (es) |
KR (1) | KR20200030048A (es) |
CN (1) | CN110997675B (es) |
AR (1) | AR112448A1 (es) |
AU (1) | AU2018299824B2 (es) |
BR (1) | BR112019025611A2 (es) |
CA (1) | CA3066922A1 (es) |
CL (1) | CL2020000056A1 (es) |
CO (1) | CO2019015102A2 (es) |
CY (1) | CY1125014T1 (es) |
DK (1) | DK3652176T3 (es) |
EA (1) | EA039526B1 (es) |
ES (1) | ES2903268T3 (es) |
HR (1) | HRP20220029T1 (es) |
HU (1) | HUE057600T2 (es) |
IL (1) | IL271799B (es) |
LT (1) | LT3652176T (es) |
MX (1) | MX2020000402A (es) |
PH (1) | PH12020500079A1 (es) |
PL (1) | PL3652176T3 (es) |
PT (1) | PT3652176T (es) |
RS (1) | RS62826B1 (es) |
SA (1) | SA519410851B1 (es) |
SG (1) | SG11201912168TA (es) |
SI (1) | SI3652176T1 (es) |
TW (1) | TWI801398B (es) |
UA (1) | UA124793C2 (es) |
WO (1) | WO2019011802A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3894409B1 (en) * | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
KR20210102955A (ko) * | 2018-12-12 | 2021-08-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 치환된 크산틴 유도체 |
IL291903A (en) * | 2019-10-04 | 2022-06-01 | Goldfinch Bio Inc | Biomarker-based treatment of focal segmental tuberous sclerosis and diabetic kidney disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1953162B9 (de) * | 2001-02-24 | 2012-10-31 | Boehringer Ingelheim Pharma GmbH & Co. KG | Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
CA2657640A1 (en) * | 2006-07-14 | 2008-01-24 | Pfizer Products Inc. | Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
MY189912A (en) | 2013-03-15 | 2022-03-21 | Hydra Biosciences Llc | Substituted xanthines and methods of use thereof |
TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位a1離子通道 |
WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
JP6667093B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC | ピリド[2,3−d]ピリミジン−2,4(1H,3H)−ジオン誘導体 |
EP3194367B1 (en) | 2014-09-17 | 2021-08-18 | Boehringer Ingelheim International GmbH | Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes |
-
2018
- 2018-07-06 EP EP18735588.8A patent/EP3652176B1/en active Active
- 2018-07-06 HR HRP20220029TT patent/HRP20220029T1/hr unknown
- 2018-07-06 RS RS20211577A patent/RS62826B1/sr unknown
- 2018-07-06 IL IL271799A patent/IL271799B/en unknown
- 2018-07-06 BR BR112019025611-3A patent/BR112019025611A2/pt unknown
- 2018-07-06 DK DK18735588.8T patent/DK3652176T3/da active
- 2018-07-06 PL PL18735588T patent/PL3652176T3/pl unknown
- 2018-07-06 CA CA3066922A patent/CA3066922A1/en active Pending
- 2018-07-06 PT PT187355888T patent/PT3652176T/pt unknown
- 2018-07-06 KR KR1020207000260A patent/KR20200030048A/ko not_active Application Discontinuation
- 2018-07-06 SG SG11201912168TA patent/SG11201912168TA/en unknown
- 2018-07-06 HU HUE18735588A patent/HUE057600T2/hu unknown
- 2018-07-06 WO PCT/EP2018/068366 patent/WO2019011802A1/en unknown
- 2018-07-06 EA EA202090270A patent/EA039526B1/ru unknown
- 2018-07-06 SI SI201830519T patent/SI3652176T1/sl unknown
- 2018-07-06 CN CN201880045961.0A patent/CN110997675B/zh active Active
- 2018-07-06 UA UAA202000735A patent/UA124793C2/uk unknown
- 2018-07-06 MX MX2020000402A patent/MX2020000402A/es unknown
- 2018-07-06 JP JP2020523041A patent/JP7114702B2/ja active Active
- 2018-07-06 ES ES18735588T patent/ES2903268T3/es active Active
- 2018-07-06 AU AU2018299824A patent/AU2018299824B2/en active Active
- 2018-07-06 LT LTEPPCT/EP2018/068366T patent/LT3652176T/lt unknown
- 2018-07-10 TW TW107123858A patent/TWI801398B/zh active
- 2018-07-10 US US16/031,399 patent/US10329292B2/en active Active
- 2018-07-11 AR ARP180101931 patent/AR112448A1/es unknown
-
2019
- 2019-12-18 SA SA519410851A patent/SA519410851B1/ar unknown
- 2019-12-30 CO CONC2019/0015102A patent/CO2019015102A2/es unknown
-
2020
- 2020-01-08 CL CL2020000056A patent/CL2020000056A1/es unknown
- 2020-01-10 PH PH12020500079A patent/PH12020500079A1/en unknown
-
2022
- 2022-01-12 CY CY20221100028T patent/CY1125014T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
CR20180320A (es) | Compuestos inhibidores de la quinasa de union a tank | |
CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
CL2016001131A1 (es) | Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones. | |
CL2016000925A1 (es) | Inhibidores de bromodominio | |
CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
CL2016001364A1 (es) | Moduladores de ror gamma (rory) | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
BR112016025787A2 (pt) | Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma | |
CL2016002835A1 (es) | “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
CL2020000056A1 (es) | Nuevos derivados de xantina sustituidos. | |
CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
CL2018003417A1 (es) | Nuevos compuestos. | |
CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
CO2017001601A2 (es) | Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio | |
CO2018008445A2 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca | |
CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
CL2015003460A1 (es) | Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica |